首页 > 市场调查报告书 > 製药

神经疾病

全球脑脊髓炎市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

市场调查报告书

商品编码

1408994

全球脑脊髓炎市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势和预测

Global Encephalomyelitis Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日期: 2024年01月01日 | 出版商:

Value Market Research | 英文 247 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

预计到 2030 年，全球脑脊髓炎市场的市场规模将从 2022 年的 212.8 亿美元达到近 348.8 亿美元，2023-2030 年研究期间CAGR为 6.37%。

脑脊髓炎是指大脑（脑）和脊髓（脊髓炎）的发炎。这可能是由于感染、自体免疫疾病和其他发炎过程引起的。这种情况可能是急性的，即突然发生并伴随严重症状，也可能是慢性的，涉及长期或復发性发炎。

市场动态

推动脑脊髓炎理解和治疗进步和发展的因素包括神经学和免疫学方面正在进行的研究进展。这些努力有助于改善诊断工具和治疗方案。提高对各种形式脑脊髓炎（例如 ADEM 或 ME/CFS）的认识措施在促进早期诊断和介入方面发挥着至关重要的作用。医学影像和诊断工具的技术创新进一步增强了准确诊断和监测脑脊髓炎的能力，塑造了研究和临床实践的方向。医疗保健专业人员、研究人员、患者权益团体和製药公司之间的合作努力促进了知识和资源的交流，促进了该领域的进步。脑脊髓炎新疗法或治疗方法的发现和开发有助于增加对医疗和製药领域的兴趣和投资，从而促进管理这种复杂疾病的进步。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具还对全球脑脊髓炎市场的每个细分市场进行了包容性评估。脑脊髓炎产业的成长和趋势为本研究提供了整体方法。

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲脑脊髓炎市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。脑脊髓炎市场的主要参与者包括Oncomed Pharmaceuticals、辉瑞公司、Immunomedics、武田製药、艾伯维公司、杨森生物技术公司、阿斯特捷利康公司、礼来公司、罗氏公司、诺华公司、拜耳公司、默克公司、安进公司、Spectrum Pharmaceuticals Inc.、葛兰素史克公司、赛诺菲公司及百时美施贵宝公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：脑脊髓炎公司的竞争格局

脑脊髓炎市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

公司股份分析
市场集中度
Oncomed Pharmaceuticals

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Immunomedics

公司简介
公司收入
产品
最近的发展

Takeda Pharmaceuticals

公司简介
公司收入
产品
最近的发展

AbbVie Inc.

公司简介
公司收入
产品
最近的发展

Janssen Biotech Inc.

公司简介
公司收入
产品
最近的发展

AstraZeneca Plc.

公司简介
公司收入
产品
最近的发展

Eli Lilly and Company

公司简介
公司收入
产品
最近的发展

F. Hoffmann-La Roche Ltd.

公司简介
公司收入
产品
最近的发展

Novartis AG

公司简介
公司收入
产品
最近的发展

Bayer AG

公司简介
公司收入
产品
最近的发展

Merck & Co. Inc.

公司简介
公司收入
产品
最近的发展

Amgen Inc.

公司简介
公司收入
产品
最近的发展

Spectrum Pharmaceuticals Inc.

公司简介
公司收入
产品
最近的发展

GlaxoSmithKline Plc.

公司简介
公司收入
产品
最近的发展

Sanofi

公司简介
公司收入
产品
最近的发展

Bristol-Myers Squibb Company

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112113252

The global demand for Encephalomyelitis Market is presumed to reach the market size of nearly USD 34.88 BN by 2030 from USD 21.28 BN in 2022 with a CAGR of 6.37% under the study period 2023 - 2030.

Encephalomyelitis refers to the inflammation of both the brain (encephalo) and the spinal cord (myelitis). This may be caused due to infections, autoimmune disorders, and other inflammatory processes. This condition can be acute, meaning it occurs suddenly with severe symptoms, or it can be chronic, involving long-term or recurrent inflammation.

MARKET DYNAMICS

The factors driving progress and developments in the understanding and management of encephalomyelitis include ongoing research advances in neurology and immunology. These efforts contribute to improved diagnostic tools and treatment options. Increased awareness initiatives focused on various forms of encephalomyelitis, such as ADEM or ME/CFS, play a vital role in promoting early diagnosis and intervention. Technological innovations in medical imaging and diagnostic tools further enhance the ability to accurately diagnose and monitor encephalomyelitis, shaping the direction of research and clinical practices. Collaborative efforts among healthcare professionals, researchers, patient advocacy groups, and pharmaceutical companies facilitate the exchange of knowledge and resources, fostering progress in the field. The discovery and development of new treatments or therapeutic approaches for encephalomyelitis contribute to increased interest and investment in the medical and pharmaceutical sectors, promoting advancements in managing this complex medical condition.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of encephalomyelitis. The growth and trends of encephalomyelitis industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the encephalomyelitis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By End-Users

Clinics
Hospitals
Others

By Treatment

Surgery
Plasmapheresis
Drug Treatment
Others

By Type

Equine Encephalomyelitis
Associated Encephalomyelitis
AntiMOG
Encephalomyelitis Disseminata
Acute Disseminated Encephalomyelitis
AIDS-Related Encephalomyelitis
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Encephalomyelitis market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Encephalomyelitis market include Oncomed Pharmaceuticals, Pfizer Inc., Immunomedics, Takeda Pharmaceuticals, AbbVie Inc., Janssen Biotech, Inc., AstraZeneca Plc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Merck & Co. Inc., Amgen Inc., Spectrum Pharmaceuticals Inc., GlaxoSmithKline Plc., Sanofi, and Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ENCEPHALOMYELITIS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By End-Users
- 3.7.2 Market Attractiveness Analysis By Treatment
- 3.7.3 Market Attractiveness Analysis By Type
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY END-USERS

5.1 Overview by End-Users
5.2 Historical and Forecast Data
5.3 Analysis by End-Users
5.4 Clinics Historic and Forecast Sales by Regions
5.5 Hospitals Historic and Forecast Sales by Regions
5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY TREATMENT

6.1 Overview by Treatment
6.2 Historical and Forecast Data
6.3 Analysis by Treatment
6.4 Surgery Historic and Forecast Sales by Regions
6.5 Plasmapheresis Historic and Forecast Sales by Regions
6.6 Drug Treatment Historic and Forecast Sales by Regions
6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY TYPE

7.1 Overview by Type
7.2 Historical and Forecast Data
7.3 Analysis by Type
7.4 Equine Encephalomyelitis Historic and Forecast Sales by Regions
7.5 Associated Encephalomyelitis Historic and Forecast Sales by Regions
7.6 AntiMOG Historic and Forecast Sales by Regions
7.7 Encephalomyelitis Disseminata Historic and Forecast Sales by Regions
7.8 Acute Disseminated Encephalomyelitis Historic and Forecast Sales by Regions
7.9 AIDS-Related Encephalomyelitis Historic and Forecast Sales by Regions
7.10. Others Historic and Forecast Sales by Regions

8 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE ENCEPHALOMYELITIS COMPANIES

9.1. Encephalomyelitis Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF ENCEPHALOMYELITIS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Oncomed Pharmaceuticals
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Pfizer Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Immunomedics
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Takeda Pharmaceuticals
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. AbbVie Inc.
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Janssen Biotech Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. AstraZeneca Plc.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Eli Lilly and Company
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. F. Hoffmann-La Roche Ltd.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Novartis AG
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Bayer AG
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments
10.14. Merck & Co. Inc.
- 10.14.1. Company Overview
- 10.14.2. Company Revenue
- 10.14.3. Products
- 10.14.4. Recent Developments
10.15. Amgen Inc.
- 10.15.1. Company Overview
- 10.15.2. Company Revenue
- 10.15.3. Products
- 10.15.4. Recent Developments
10.16. Spectrum Pharmaceuticals Inc.
- 10.16.1. Company Overview
- 10.16.2. Company Revenue
- 10.16.3. Products
- 10.16.4. Recent Developments
10.17. GlaxoSmithKline Plc.
- 10.17.1. Company Overview
- 10.17.2. Company Revenue
- 10.17.3. Products
- 10.17.4. Recent Developments
10.18. Sanofi
- 10.18.1. Company Overview
- 10.18.2. Company Revenue
- 10.18.3. Products
- 10.18.4. Recent Developments
10.19. Bristol-Myers Squibb Company
- 10.19.1. Company Overview
- 10.19.2. Company Revenue
- 10.19.3. Products
- 10.19.4. Recent Developments